Loading...

EBS EMERGENT BIOSOLUTIONS INC Disposals and divestitures 8-K Filing

MRGN

BS

EMERGENT BIOSOLUTIONS INC

(EBS)

2025 8-K

FDA Approval Received

Board Member Retirement

Quarterly Results Report

Contract Modification

Contract Enhancement

Financial Statements

Contract Renewal

Civil, Criminal Litigations

Financial Statements

Earnings Announcement

Investor Presentation

Commercial Rights Agreement

Contract Modifications

Earnings Announcement

Credit Agreement

Equity Issuance

Term Loan Agreement

Financial Results Announcement

Settlement Agreement with J...

Contract Modifications

Annual Meeting Approval

Contract Modification and F...

Restructuring Plan

Entry into Material Definit...

Amendment of Senior Secured...

Appointment of CEO

Participation in Conference

Contract Option

Restatement of Financial Re...

Results of Operations and F...

Departure of Directors

Restructuring Plan and Depa...

Compensation Agreements

Post-Market Approval

Management Change

Amendment to Stock Incentiv...

Contract Modification

Amendment and Extension of ...

Completion of Acquisition o...

Agreement Amendment

FDA Approval of NARCAN Nasa...

Departure of Chief Strategy...

Sale of Travel Health Business

Financial Results and Restr...

External Links:

On March 10, 2025, Emergent BioSolutions Inc. announced it will sell its Baltimore-Bayview drug manufacturing facility to Syngene USA Inc. for about $36.5 million, while retaining rights for future manufacturing services.

AI Assistant

EMERGENT BIOSOLUTIONS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.